Cargando…

Neoadjuvant chemotherapy combined with endocrine therapy for hormone receptor-positive breast cancer: A systematic review and meta-analysis

BACKGROUND: This study aimed to conduct a comparative analysis of the efficacy and safety of neoadjuvant chemotherapy combined with endocrine therapy against the backdrop of single neoadjuvant chemotherapy or endocrine therapy, specifically in the context of hormone receptor-positive (HR+) breast ca...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ma, Hong-Fang, Shen, Jun, Xu, Bin, Shen, Jian-Guo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	5750
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10659694/ https://www.ncbi.nlm.nih.gov/pubmed/37986364 http://dx.doi.org/10.1097/MD.0000000000035928

Ejemplares similares

Endocrine therapies in postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative, pretreated, advanced breast cancer: A network meta-analysis
por: Lee, Cho-Hao, et al.
Publicado: (2020)

Application of neoadjuvant chemotherapy in occult breast cancer: Five case reports
por: Yang, Haisong, et al.
Publicado: (2017)

Adjuvant ovarian suppression for premenopausal hormone receptor-positive breast cancer: A network meta-analysis
por: Jiang, Mengjie, et al.
Publicado: (2021)

Efficacy and safety of endocrine monotherapy as first-line treatment for hormone-sensitive advanced breast cancer: A network meta-analysis
por: Zhang, Jingwen, et al.
Publicado: (2017)

Elevated expression of MTDH predicts better prognosis of locally advanced HER-2 positive breast cancer patients receiving neoadjuvant chemotherapy plus trastuzumab
por: Wang, Xinle, et al.
Publicado: (2019)

Chemotherapy-induced prospective memory impairment in breast cancer patients with different hormone receptor expression
por: Li, Wen, et al.
Publicado: (2017)

Ki-67 labeling index is a predictive marker for a pathological complete response to neoadjuvant chemotherapy in breast cancer: A meta-analysis
por: Tao, Miaomiao, et al.
Publicado: (2017)

High expression of MORC2 predicts worse neoadjuvant chemotherapy efficacy in triple negative breast cancer
por: Liao, Xiaohong, et al.
Publicado: (2023)

Adjuvant endocrine therapy alone in patients with node-positive, luminal A type breast cancer
por: Park, Sungmin, et al.
Publicado: (2017)

Value of Breast Cancer Molecular Subtypes and Ki67 Expression for the Prediction of Efficacy and Prognosis of Neoadjuvant Chemotherapy in a Chinese Population
por: Wang, Jiayu, et al.
Publicado: (2016)

Management of the axilla with sentinel lymph node biopsy after neoadjuvant chemotherapy for breast cancer: A single-center study
por: Aksoy, Suleyman Ozkan, et al.
Publicado: (2020)

Background Parenchymal Enhancement on Preoperative Magnetic Resonance Imaging: Association With Recurrence-Free Survival in Breast Cancer Patients Treated With Neoadjuvant Chemotherapy
por: Choi, Ji Soo, et al.
Publicado: (2016)

Combination of (125)I brachytherapy and chemotherapy for unresectable recurrent breast cancer: A retrospective control study
por: Tan, Qixing, et al.
Publicado: (2016)

Neoadjuvant chemotherapy reduces the expression rates of ER, PR, HER2, Ki67, and P53 of invasive ductal carcinoma
por: Peng, Jian-Heng, et al.
Publicado: (2019)

Efficacy and safety of Kanglaite injection combined with chemotherapy for women breast cancer: A protocol for systematic review and meta-analysis of randomized clinical trials
por: Cheng, Shengli, et al.
Publicado: (2021)

Expression of hormone receptors in low-grade adenosquamous carcinoma of the breast: A case report
por: Wu, Hai-Bo, et al.
Publicado: (2017)

The curative effects of radiotherapy-based therapies for human epidermal growth factor receptor 2-positive breast cancer: A meta-analysis
por: Shao, Minghai, et al.
Publicado: (2017)

Prognostic value of long non-coding RNAs in triple negative breast cancer: A PRISMA-compliant meta-analysis
por: Zhang, Shuo, et al.
Publicado: (2020)

Real-world effectiveness and sensitivity of palbociclib plus endocrine therapy in HR+/HER2– patients with metastatic breast cancer
por: Li, Jingping, et al.
Publicado: (2021)

Comparative efficacy and safety of metronomic chemotherapy in breast cancer: A protocol for network meta-analysis protocol
por: Xie, Ying, et al.
Publicado: (2021)

The duration of endocrine therapy and breast cancer patients’ survival: A nationwide population-based cohort study
por: Chang, Chuan-Hsun, et al.
Publicado: (2019)

Impact of Breast Cancer Subtype Defined by Immunohistochemistry Hormone Receptor and HER2 Status on the Incidence of Immediate Postmastectomy Reconstruction
por: Wu, Wei, et al.
Publicado: (2016)

Combination of Chinese medicinal formulas and chemotherapy for triple-negative breast cancer strengthens body resistance to eliminate pathogenic factors
por: Zhang, Yiyi, et al.
Publicado: (2022)

Vitamin D Receptor Polymorphism and Breast Cancer Risk: A Meta-Analysis
por: Lu, Demin, et al.
Publicado: (2016)

Impact of patient race and geographical factors on initiation and adherence to adjuvant endocrine therapy in medicare breast cancer survivors
por: Camacho, Fabian T., et al.
Publicado: (2017)

A phase I study of pharmacokinetics of trastuzumab emtansine in Chinese patients with locally advanced inoperable or metastatic human epidermal growth factor receptor 2-positive breast cancer who have received prior trastuzumab-based therapy
por: Ji, Dongmei, et al.
Publicado: (2020)

Concomitant fulvestrant with reirradiation for unresectable locoregional recurrent estrogen receptor positive (ER+) breast cancer: A case report and narrative review
por: Ding, Jingxian, et al.
Publicado: (2020)

Bacterial extracellular vesicles affect endocrine therapy in MCF7 cells
por: An, Jeongshin, et al.
Publicado: (2021)

Pathological complete response to neoadjuvant trastuzumab and pertuzumab therapy is related to human epidermal growth factor receptor 2 (HER2) amplification level in HER2-amplified breast cancer
por: Choi, Jin Hyuk, et al.
Publicado: (2020)

Highly durable response to capecitabine in patient with metastatic estrogen receptor positive breast cancer: A case report
por: Barchiesi, Giacomo, et al.
Publicado: (2019)

Pyrotinib in the treatment of human epidermal growth factor receptor 2-positive metastatic breast cancer: A case report
por: Dai, Jiali, et al.
Publicado: (2020)

Positive estrogen receptor status is a poor prognostic factor in node-negative breast cancer: An observational study in Asian patients
por: Jung, Eun Jung, et al.
Publicado: (2021)

Trastuzumab improves locoregional control in HER2-positive breast cancer patients following adjuvant radiotherapy
por: Cao, Lu, et al.
Publicado: (2016)

Diabetes mellitus and prognosis in women with breast cancer: A systematic review and meta-analysis
por: Zhao, Xiao-Bo, et al.
Publicado: (2016)

Effects of Baduanjin on postoperative rehabilitation of patients with breast cancer: A protocol for systematic review and meta-analysis
por: Chen, Guangyan, et al.
Publicado: (2021)

Diagnosis and treatment of advanced HER2-positive breast cancer in young pregnant female: A case report
por: Tang, Tiantian, et al.
Publicado: (2020)

Survival outcomes in patients with human epidermal growth factor receptor 2 positive metastatic breast cancer administered a therapy following trastuzumab emtansine treatment
por: Watanuki, Rurina, et al.
Publicado: (2020)

Changes in HER2 status and survival outcomes in patients with non-pathological complete response after neoadjuvant targeted treatment
por: Ren, Xiaofei, et al.
Publicado: (2023)

Adjuvant chemotherapy-associated lipid changes in breast cancer patients: A real-word retrospective analysis
por: He, Tao, et al.
Publicado: (2020)

Induced abortion and breast cancer: An updated meta-analysis
por: Deng, Yongchun, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_5rscah9meuuljnrm22gia7j8ah